tiprankstipranks
Biogen (BIIB)
NASDAQ:BIIB

Biogen (BIIB) Stock Forecast & Price Target

4,378 Followers
See the Price Targets and Ratings of:

BIIB Analyst Ratings

Strong Buy
25Ratings
19 Buy
6 Hold
0 Sell
Based on 25 analysts giving stock ratings to
Biogen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$283.05
▲(22.17% Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $283.05 with a high forecast of $342.00 and a low forecast of $200.00. The average price target represents a 22.17% change from the last price of $231.69.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"199":"$199","235":"$235","271":"$271","307":"$307","343":"$343"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":342,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$342.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":283.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$283.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$200.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[199,235,271,307,343],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,225.43,234.3969230769231,243.36384615384617,252.33076923076925,261.29769230769233,270.2646153846154,279.2315384615385,288.1984615384615,297.1653846153846,306.1323076923077,315.09923076923076,324.06615384615384,333.0330769230769,{"y":342,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,225.43,229.8623076923077,234.29461538461538,238.72692307692307,243.1592307692308,247.59153846153848,252.02384615384616,256.4561538461539,260.88846153846157,265.32076923076926,269.75307692307695,274.18538461538463,278.6176923076923,{"y":283.05,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,225.43,223.47384615384615,221.5176923076923,219.56153846153848,217.60538461538462,215.64923076923077,213.69307692307692,211.7369230769231,209.78076923076924,207.82461538461538,205.86846153846153,203.9123076923077,201.95615384615385,{"y":200,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":297.48,"date":1686873600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.07,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268.92,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":267.17,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.25,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":249.5,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":234.64,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":257.88,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.72,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":220.95,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.87,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":217.51,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.43,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$342.00Average Price Target$283.05Lowest Price Target$200.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial
Buy
Reiterated
05/23/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (NASDAQ: BIIB) and Incyte (NASDAQ: INCY)
Morgan Stanley
$331.00
Buy
42.86%
Upside
Reiterated
05/22/24
Morgan Stanley on Biogen (BIIB) Acquisition of Hi-BioMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $331.00 price target on Biogen (NASDAQ: BIIB)
William Blair
Buy
Reiterated
05/22/24
Biogen acquiring HI-Bio in increased immunology focus, says William BlairBiogen acquiring HI-Bio in increased immunology focus, says William Blair
Piper Sandler
$335.00
Buy
44.59%
Upside
Reiterated
05/22/24
Piper Sandler reiterates Overweight Rating on Biogen (BIIB) Following Acquisition of HI-BioPiper Sandler reiterates Overweight Rating on Biogen (BIIB) Following Acquisition of HI-Bio
BMO Capital
$260.00
Buy
12.22%
Upside
Assigned
05/22/24
Buy Rating Affirmed for Biogen on Strategic Acquisition and Promising Pipeline

Best Analysts Covering Biogen

Which Analyst Should I Follow If I Want to Buy BIIB and Sell After:
1 Month
Salim SyedMizuho Securities
Success Rate
14/29 ratings generated profit
48%
Average Return
+0.92%
assigned a buy rating 2 months ago
Copying Salim Syed's trades and holding each position for 1 Month would result in 48.28% of your transactions generating a profit, with an average return of +0.92% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Brian AbrahamsRBC Capital
Success Rate
14/22 ratings generated profit
64%
Average Return
+4.01%
reiterated a buy rating 12 days ago
Copying Brian Abrahams's trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +4.01% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Brian AbrahamsRBC Capital
Success Rate
11/22 ratings generated profit
50%
Average Return
+3.53%
reiterated a buy rating 12 days ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +3.53% per trade.
2 Years
Marc GoodmanLeerink Partners
Success Rate
15/36 ratings generated profit
42%
Average Return
-6.58%
reiterated a buy rating 26 days ago
Copying Marc Goodman's trades and holding each position for 2 Years would result in 41.67% of your transactions generating a profit, with an average return of -6.58% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating
Feb 24
Mar 24
Apr 24
May 24
Jun 24
Strong Buy
6
6
17
13
12
Buy
34
30
35
33
32
Hold
11
11
16
13
13
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
51
47
68
59
57
In the current month, BIIB has received 44 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. BIIB average Analyst price target in the past 3 months is $283.05.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $3.99 with a range of $3.40 to $6.04. The previous quarter’s EPS was $3.67. BIIB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.24% of the time in the same period. In the last calendar year BIIB has Outperformed its overall industry.
Next quarter’s earnings estimate for BIIB is $3.99 with a range of $3.40 to $6.04. The previous quarter’s EPS was $3.67. BIIB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.24% of the time in the same period. In the last calendar year BIIB has Outperformed its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.38B with a range of $2.32B to $2.45B. The previous quarter’s sales results were $2.20B. BIIB beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.55% of the time in the same period. In the last calendar year BIIB has Underperformed its overall industry.
Next quarter’s sales forecast for BIIB is $2.38B with a range of $2.32B to $2.45B. The previous quarter’s sales results were $2.20B. BIIB beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.55% of the time in the same period. In the last calendar year BIIB has Underperformed its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen’s 12-month average price target is $283.05.
    What is BIIB’s upside potential, based on the analysts’ average price target?
    Biogen has 22.17% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BIIB a Buy, Sell or Hold?
          Biogen has a consensus rating of Strong Buy which is based on 19 buy ratings, 6 hold ratings and 0 sell ratings.
            What is Biogen’s price target?
            The average price target for Biogen is $283.05. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $342.00 ,the lowest forecast is $200.00. The average price target represents 22.17% Increase from the current price of $231.69.
              What do analysts say about Biogen?
              Biogen’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of BIIB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis